

August 4, 2026

Listing Department, National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Symbol: ARTEMISMED	Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 542919
---	---

Sub: Intimation of newspaper publication of Un-audited Financial Results

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of un-audited financial results for the quarter ended June 30, 2026, published in the following newspapers on August 4, 2026:

- The Financial Express (English National Daily Newspaper- all editions);
- The Jansatta (Hindi National Daily Newspaper- Delhi edition).

The aforesaid results are also accessible on the Company's website at <https://www.artemishospitals.com/investors>.

This is for your information and records.

Thanking you,

Yours faithfully,

For Artemis Medicare Services Limited

Poonam Makkar

Company Secretary & Compliance Officer

Encl.: As above



HERO FINCORP LIMITED
 Registered office: 94, Community Centre, Basant Lok, Vasant Vihar, New Delhi - 110057
 Corporate office: 9, Community Centre, Basant Lok, Vasant Vihar, New Delhi - 110057 Tel. No: 011-49487150, Website: www.herofincorp.com | CIN: U74899DL1991PLC046774

PUBLIC NOTICE
 Hero FinCorp Limited hereby notifies that, with an objective to rationalize its corporate office, situated at the below address, shall be closed with effect from **November 04, 2026:**
"9, Community Centre, Basant Lok, Vasant Vihar, New Delhi-110057"
 Please note that the closure of the above corporate office shall not affect servicing of the Company's customers in any manner
 For any further details, please contact the Company's representatives through following channels:

#	Contact No.	Email ID
Retail	18001024145	customer.care@herofincorp.com
Corporate	18001035271	corporate.care@herofincorp.com

THE KANGRA CENTRAL COOPERATIVE BANK LIMITED,
 HEAD OFFICE DHARAMSHALA (HP) - 176 215
 NOTICE FOR INVITING REQUEST FOR PROPOSAL (RFP)
 RFP Notice No. KCCB/IT/2026/CCTVSS/A

Request for Proposals are invited for the "Supply, Installation, Testing, Commissioning, and Comprehensive Maintenance of an IP-Based CCTV Surveillance System for the Bank under a buy-back arrangement.". RFP document can be downloaded from the Bank website <http://www.kccbhp.bank.in> from 10:00AM on 04/08/2026.

Date of Pre bid meeting: at 11:30 AM on Tuesday, 18.08.2026.

Last date of submission of Bid: on or before 2:00 PM on Thursday, 10.09.2026..

Venue for above activities: Kangra Central Cooperative Bank Limited, Head Office Dharamshala, Distt. Kangra (HP) 176 215.

Sd/-
General Manager

ETHOS LIMITED
 Corporate Identity Number: L52300HP2007PLC030800
 Registered Office: Plot No. 3, Sector- III, Parwanoo, Himachal Pradesh -173 220.
 Telephone: + (91) 1792 232 462/233 402. Website: www.ethoswatches.com;

EXTRACT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026
 (Rupees in lakhs unless otherwise stated)

S. No.	Particulars	Standalone			Consolidated		
		Quarter ended	Year ended	Quarter ended	Quarter ended	Year ended	Quarter ended
		June 30, 2026	March 31, 2026	June 30, 2025	June 30, 2026	March 31, 2026	June 30, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)
1	Total income from operations	46,124.04	1,65,311.97	35,203.69	47,504.25	1,65,840.54	35,215.40
2	Net Profit for the period from ordinary activities (before tax, exceptional items and/or extraordinary items)	3,760.88	12,918.53	2,739.64	3,913.01	13,267.29	2,611.61
3	Net Profit for the period from ordinary activities before tax (after exceptional items and/or extraordinary items)	3,760.88	12,746.95	2,739.64	3,913.01	13,085.16	2,611.61
4	Net Profit for the period from ordinary activities after tax (after exceptional items and/or extraordinary items)	2,799.24	9,492.23	2,030.33	2,866.37	9,613.88	1,901.91
5	Total Comprehensive Income for the period [comprising profit for the period(after tax) and other comprehensive income(after tax)]	2,799.24	9,516.32	2,030.33	2,818.73	9,950.13	2,172.36
6	Paid-up equity share capital (Face value in Rs. 10 per share)	2,675.77	2,675.77	2,448.04	2,675.77	2,675.77	2,448.04
7	Reserves (excluding revaluation reserves)						
8	Earnings per share (of Rs. 10/- each) (not annualized):						
	(a) Basic (Rs.)	10.46	36.27	8.29	10.51	36.21	7.77
	(b) Diluted (Rs.)	10.46	36.27	8.29	10.51	36.21	7.77

Notes:

- The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meetings held on August 03, 2026. The unaudited financial results for the current quarter ended June 30, 2026 have been reviewed by the Statutory Auditors of the Company. The unmodified audit report of the Statutory Auditors is being filed with the BSE and National Stock Exchange of India Limited.
- The above is the extract of the detailed format of the unaudited quarterly ended financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited quarterly ended financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and the company's website at www.ethoswatches.com.

For and on behalf of the
Board of Directors of Ethos Limited
Pranav Shankar Saboo
Managing Director and Chief Executive Officer
(DIN - 03391925)
CONCEPT

Place: Gurugram
Date: August 03, 2026

ARTEMIS MEDICARE SERVICES LIMITED
 CIN: L85110DL2004PLC126414
 Regd. Office: Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075
 Ph.: +91-124-4511111
 Email: investor@artemishospitals.com | Website: www.artemishospitals.com

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026
 (₹ in Lacs)

S. No.	Particulars	Quarter Ended		Year Ended
		30-Jun-26	30-Jun-25	31-Mar-26
		(Unaudited)	(Audited)	(Audited)
1	Total Income from Operations	28,732.35	25,496.09	1,08,124.24
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary Items)	4,263.04	2,978.44	14,225.22
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary Items)	4,263.04	2,978.44	13,917.78
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary Items)	3,144.27	2,119.75	10,371.52
5	Total Comprehensive Income for the period [comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,140.61	2,115.59	10,353.47
6	Paid-up Equity Share Capital (Face value Re.1/-each)	1,583.06	1,389.32	1,583.06
7	Reserves (excluding Revaluation Reserve)			84,995.12
8	Earning per Equity Share (Face value Re.1/-each)			
	(a) Basic	1.98*	1.35*	6.56
	(b) Diluted	1.98*	1.35*	6.56
	(* Not annualised)			

Notes:

- The key standalone financial information of the Company is as under:

ARTEMIS MEDICARE SERVICES LIMITED
 CIN: L85110DL2004PLC126414
 Regd. Office: Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075
 Ph.: +91-124-4511111
 Email: investor@artemishospitals.com | Website: www.artemishospitals.com

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026
 (₹ in Lacs)

S. No.	Particulars	Quarter Ended		Year Ended
		30-Jun-26	30-Jun-25	31-Mar-26
		(Unaudited)	(Audited)	(Audited)
1	Total Income from Operations	28,200.97	24,979.86	1,06,049.17
2	Net Profit for the period before Tax (after Exceptional Items)	4,210.98	3,006.71	13,868.45
3	Net Profit for the period after Tax	3,105.11	2,141.72	10,344.15

- The unaudited financial results for the quarter ended June 30, 2026 were reviewed by the Audit Committee at its meeting held on August 3, 2026 and have been approved by the Board of Directors of the Company at its meeting held on August 3, 2026.
- The above is an extract of the detailed format of quarter ended June 30, 2026 financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarter ended June 30, 2026 financial results (Consolidated/ Standalone) are available on the Stock Exchange websites [National Stock Exchange of India Limited (www.nseindia.com) & BSE Limited (www.bseindia.com)] and on the Company's website (www.artemishospitals.com/investors). The same can also be accessed by scanning the Quick Response (QR) code provided below:

For and on behalf of the Board of Directors of
Artemis Medicare Services Limited
Sd/-
Onkar Kanwar
Chairman

Place : Gurugram
Dated: August 3, 2026

KALPATARU LIMITED
 CIN: L45200MH1988PLC050144
 Registered Office: 91, Kalpataru Synergy, Opposite Grand Hyatt, Santacruz (East), Mumbai - 400055.
 Tel : +91 22 30645000; Website – www.kalpataru.com; Email : investor.cs@kalpataru.com

UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2026

The Board of Directors of the Company at its meeting held on August 03, 2026 has approved the Unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. The Unaudited Standalone and Consolidated Financial Results of the Company along with the Limited Review Reports thereon ('Results'), are available on the websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com and on Company's website at <https://www.kalpataru.com/investor-corner>. The Results can also be accessed by scanning the Quick Response Code provided below.

For Kalpataru Limited

Parag Munot
Managing Director
(DIN - 00136337)

Date: August 03, 2026
Place: Mumbai

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES NOR IS IT A PROSPECTUS ANNOUNCEMENT. **NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.** INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS")

ARJUN JEWELLERS LIMITED
 Registered & Corporate Office: Office No. 401, 4th Floor, Pride Capital, Jalaram 1, Street No.2, University Road, Rajkot Sau Uni Area, Rajkot- 360 005, Gujarat, India.
 Tel: 02813500800; Contact Person: Limbasiya Pradip Mansukhbhai, Company Secretary and Compliance Officer, E-mail: compliance@arjunjewellers.in
 Website: <https://arjunjewellers.in/>; Corporate Identity Number: U36100GJ2020PLC111829

OUR PROMOTERS: MANISHBHAI NATHUBHAI GHADIYA AND GHADIYA RASWANTI MANISH

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF ARJUN JEWELLERS LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹ 2,000 MILLION (THE "ISSUE"). THE ISSUE SHALL CONSTITUTE [•] % OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF EQUITY SHARES IS ₹ 10 EACH. THE ISSUE PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND, AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER AND WILL BE ADVERTISED IN ALL EDITIONS OF [•] AN ENGLISH NATIONAL DAILY NEWSPAPER (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), ALL EDITIONS OF [•] A HINDI NATIONAL DAILY NEWSPAPER (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND [•] EDITIONS OF [•] (A WIDELY CIRCULATED GUJARATI DAILY NEWSPAPER, GUJARATI BEING THE REGIONAL LANGUAGE OF RAJKOT, GUJARAT WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE AND NSE (TOGETHER WITH BSE AND NSE, THE "STOCK EXCHANGES") FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").

In case of any revision to the Price Band, the Bid/ Issue Period will be extended by at least three additional Working Days following such revision of the Price Band, subject to the Bid/ Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, in consultation with the Book Running Lead Manager, for reasons to be recorded in writing, extend the Bid/ Issue Period for a minimum of one Working Day, subject to the Bid/ Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the Book Running Lead Manager and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks ("SCSBs"), other Designated Intermediaries and the Sponsor Banks, as applicable.

The Issue is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended, read with Regulation 31 of the SEBI ICDR Regulations. The Issue is being made through the Book Building Process, in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein in terms of Regulation 32 (1) of the SEBI ICDR Regulations, not more than 50% of the Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIBs" and such portion, "QIB Portion"), provided that our Company in consultation with the BRLM, may allocate up to 60% of the QIB Category to Anchor Investors, on a discretionary basis (the "Anchor Investor Portion") out of which at least 40% shall be available for allocation as under (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and pension funds, subject to valid Bids being received from the domestic Mutual Funds, Life Insurance Companies and pension funds at or above the Anchor Investor Allocation Price. Any under-subscription in the reserved category specified in clause (ii) above may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance equity shares of face value of ₹10 each shall be added to the remaining QIB Portion ("Net QIB Portion"). Further, 5% of the Net QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders out of which (a) one-third of such portion shall be reserved for bidders with application size of more than ₹0.2 million and up to ₹1.00 million; and (b) two-third of such portion shall be reserved for bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to bidders in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders ("RIBs") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank accounts (including UPI ID for UPI Bidders using UPI Mechanism) (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the SCSBs or the Sponsor Banks, as applicable, to participate in the Issue. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Issue through the ASBA process. For details, specific attention is invited to "Issue Procedure" on page 401 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Issue and has filed the DRHP dated August 1, 2026, with the Securities and Exchange Board of India ("SEBI") and with the Stock Exchanges. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of such filing by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com, on the website of the Company at <https://arjunjewellers.in/> and on the website of the Book Running Lead Manager ("BRLM"), i.e. Saffron Capital Advisors Private Limited at www.saffronadvisor.com. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The members of the public are requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLM at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLM in relation to the Issue on or before 5.00 p.m. on the 21st day from the aforesaid date of publication of this public announcement.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Issue unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, Bidders must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares offered in the Issue have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" beginning on page 23 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after a Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in RHP from DRHP. The Equity Shares, when offered through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the memorandum and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 88 of the DRHP. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on pages 239 of the DRHP.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
 Saffron Capital Advisors Private Limited 605, Sixth Floor, Centre Point, Andheri Kurla Road, JB. Nagar, Andheri East, Mumbai-400 059, Maharashtra, India. Tel : +91-22-49730394 E-mail : ipos@saffronadvisor.com Website: www.saffronadvisor.com Investor grievance E-mail: investorgrievance@saffronadvisor.com Contact Person: Mr Vipin Gupta / Mr Sachin Prajapati SEBI Registration No: INM000011211	 MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited) C- 101, Embassy 247, L.B.S Marg, Vikhroli (West), Mumbai – 400 083, Maharashtra, India Telephone: + 91 810 811 4949 E-mail: arjunjewellers ipo@in.mpms.mufg.com Investor grievance e-mail: arjunjewellers ipo@in.mpms.mufg.com Website: www.in.mpms.mufg.com Contact Person: Shanti Gopalakrishnan SEBI registration number: INR000004058

